RiMO-HNC-NEO1NCT07732634
Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer
At risk: Primary completion moved at least 2 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 10 more changesShow less
- Primary endpoint(s) modified
- Lead sponsor: University of Illinois at Chicago to University of Illinois Chicago
- Eligibility criteria expanded, about 35 words
- Primary completion pushed from Aug 2029 to Nov 2029
- Study completion pushed from Aug 2031 to Nov 2031
- Start date changed from estimate of Aug 2026 to Nov 9, 2026
- Secondary endpoints: 7 to 6
- Site details revised
- Study title shortened, about 6 words
- Study description shortened, about 5 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
RiMO-301 will be injected intratumorally once prior to radiotherapy. Radiotherapy will start within 1 day after the RiMO-301 injection for 5 fractions of 4-5 Grays per fraction over a period of 5-15 days. Pembrolizumab 200 mg will be administered intravenously every 3 weeks (Q3W) within the first dose given on the same day as the RiMO-301 injection (+/-1 day). Pembrolizumab will continue for 2 cycles (1 cycle = 21 days). Surgical resection of the tumor will occur after the completion of neoadjuvant therapy.
Drugs: RiMO-301, Pembrolizumab
Radiation: Radiation
Procedures: Surgical resection
Sites
1 site in 1 country
- University of Illinois at ChicagoChicago, Illinois, United States